Opinion

Video

Key Barriers in Implementing Guideline-Directed Cholesterol Treatment

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP

Clinical pharmacists discuss how to address key barriers that get in the way of implementing guideline-directed cholesterol treatment.

Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
Related Content
FDA approval stamp for chenodiol -- Image credit: Olivier Le Moal | stock.adobe.com
Published: February 21st 2025 | Updated: February 21st 2025

Chenodiol, First Treatment for Cerebrotendinous Xanthomatosis, Receives FDA Approval

Gillian McGovern, Associate Editor
Doctor using stethoscope take a tap on the patient's arm and pressing pressure gauge button
February 20th 2025

Fluctuating Cholesterol Over Time Associated With Dementia Risk in Older Adults

Luke Halpern, Assistant Editor
Clogged arteries, Cholesterol plaque in the artery
February 13th 2025

FDA Accepts BLA for Lerodalcibep, a Novel Agent to Lower LDL Cholesterol in Atherosclerotic Cardiovascular Disease

Luke Halpern, Assistant Editor
Partly blocked vessel in high level of LDL (bad cholesterol) lipoprotein – isometric view 3d illustration
February 5th 2025

Study: Mechanisms Impacting LDL-C Are Inversely Associated With Type 2 Diabetes Risk

Luke Halpern, Assistant Editor
Stroke is also known to be driven by hypertension, diabetes, and dyslipidemia. | Image Credit: peterschreiber.media | stock.adobe.com
February 4th 2025

Findings Suggest Hemoglobin A1c, HDL-C Associated With Increased Risk of Stroke

Ashley Gallagher, Editor
Chronic Obstructive Pulmonary Disease, Cholesterol, ApoA-I | Image Credit: surasak | stock.adobe.com
January 28th 2025

Investigators Find Causal Link Between Apolipoprotein A-I and COPD

Ashley Gallagher, Editor